|
Persistent and Marked Inactivation of O-6-Alkylguanine-DNA Alkyltransferase (AGAT), a Mechanism of Resistance to Alkylators, with Protracted Low-Dose Oral Schedules of Temozolamide. |
| |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck Serono; Merck Serono; Novartis; Novartis; Novartis; Pfizer; Sanofi; Sanofi; Sirtex Medical |
Research Funding - Baxalta/Shire |
Travel, Accommodations, Expenses - Ipsen; Ipsen |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Novartis |
| |
|
Consulting or Advisory Role - Bayer; Celgene; Sanofi |
Research Funding - Celgene (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Celgene; Roche; Sanofi |